Introduction
Autologous hematopoietic SCT can be a curative procedure when used to treat certain hematological malignancies. PBSCs have progressively replaced BM as the source of stem cells for autologous transplant. [1] [2] [3] Current data suggest that greater than 2.0 Â 10 6 CD34 þ cells/kg are needed to assure reliable and sustained hematopoietic recovery after auto-SCT. [4] [5] [6] Failure to transplant a sufficient number of hematopoietic stem cells can lead to delayed engraftment or graft failure. PBSCs are collected through apheresis after treatment with chemomobilization with cytokine support, usually G-CSF, or with mobilization using cytokine alone. A number of otherwise eligible patients fail to mobilize sufficient number of PBSCs, thereby precluding the planned high-dose therapy and transplant. The risk of insufficient PBSC mobilization has led to a search for novel mobilization strategies.
Plerixafor (AMD3100) is a reversible inhibitor for the binding of stromal derived factor-1 alpha (SDF-1a) to its receptor CXCR4. [7] [8] [9] The SDF-1a/CXCR4 complex plays a critical role in the retention of hematopoietic stem cells within the BM. 10, 11 Inhibiting this complex by downregulation through either G-CSF or the receptor antagonist, AMD3100, can lead to an increased number of PBSCs. 12, 13 The bicyclam, plerixafor, was first developed as a smallmolecule selective antagonist of the chemokine receptor CXCR4 for the treatment of HIV-1 infections. During these trials, it was observed that plerixafor elicited a transient leukocytosis in healthy volunteers as well as HIV-1-infected individuals. 14, 15 Subsequently, the role of plerixafor in the mobilization of PBSCs for auto-SCT was explored. 16, 17 Plerixafor has been shown to rapidly increase circulating CD34 þ progenitor cells in preclinical murine models and healthy volunteers alone or in combination with G-CSF. [17] [18] [19] Other clinical trials were performed combining plerixafor and G-CSF for multiple myeloma or non-Hodgkin's lymphoma patients in first or second complete or PR planned for auto-SCT. Significant enhancement of PBSC mobilization was shown. [20] [21] [22] [23] [24] [25] [26] We evaluated the results of combined use of plerixafor and G-CSF in 20 patients who had previously failed to mobilize sufficient PBSCs, to allow the patients to proceed to auto-SCT, after obtaining consent for compassionate use of the experimental agent. Of the 20 patients, 5 had failed previous chemotherapy-based PBSC mobilization and 15 failed previous cytokine-only mobilization. We report that 17 of the 20 were successfully mobilized with the combination of plerixafor plus G-CSF in one apheresis series and 18 in two aphereses series.
Patients, materials and methods

Patients
Twenty patients (Table 1) have been enrolled in a local Institutional Review Board approved compassionate-use protocol using the investigational drug plerixafor (formerly AnorMED Inc., Langley, British Columbia, Canada; now Genzyme Inc., Cambridge, MA, USA) in combination with G-CSF (Amgen Inc., Thousand Oaks, CA, USA). A total of 15 males and 5 females with a median age of 58 (range 35-71) years were enrolled. The patients were exposed to a median of 2 (range 0-8) previous treatment regimens. In earlier collection attempts, they had collected a median of 0.21 (range 0-1.8) Â 10 6 CD34 þ cells/kg in 2 (range 0-4) days. The median time from chemotherapy to first attempt at mobilization was 49 days. Patients were eligible for the protocol, AMD3100-CUP001, if they were identified as potentially benefiting from an auto-SCT but had failed to collect enough CD34 þ cells with conventional mobilization or, in the opinion of the physician, would not collect enough PBSCs on the basis of peripheral CD34 þ cell measurements after standard mobilization. A target was that patients proceeded to mobilization on the compassionate-use protocol no sooner than 2 weeks and no later than 4 weeks after the determination that they would not collect sufficient PBSCs, and all but four patients were treated within that window. Details of the premobilization clinical course of these patients are found within Table 1 .
Materials and methods
The treatment protocol consisted of treatment with G-CSF (10 mg/kg) for 4 days before apheresis. On the evening of the fourth day, plerixafor (240 mg/kg) was administered subcutaneously 10-11 h before apheresis. G-CSF (10 mg/kg) was given on day five subcutaneously, 1 h before apheresis. If multiple days of collection were required, the same schedule of plerixafor and G-CSF was maintained.
PBSCs were collected on a COBE Spectra apheresis system (Gambro BCT, Lakewood, CO, USA) with apheresis limited to processing of 10-12 l of blood per procedure. CD34 þ determination was performed using standard flow cytometry analysis (Beckman Coulter Inc., Stem-Kit Fullerton, CA, USA) and cells were cryopreserved using an institutional, Foundation for the Accreditation of Cellular Therapy-approved, cryopreservation protocol.
All experimental data are represented as medians (ranges). Paired comparisons between the two mobilizations were performed using the Student's t-test. Comparisions between institution means and study patients were performed using a one-sample t-test. A two-tailed P-value of less than 0.05 was considered statistically significant. Analyses were carried out using the statistical software SPSS (version 15.0, SPSS Inc., Chicago, IL, USA).
Results
Eighteen of the 20 patients, with non-Hodgkin's lymphoma (10), Hodgkin's disease (1), multiple myeloma (6) and angioimmunoblastic lymphadenopathy with dysproteinaemia (1), who underwent salvage stem cell mobilization using plerixafor and G-CSF were able to yield sufficient PBSCs to proceed to auto-SCT (Figures 1 and 2 ; Table 2 ). Collections from these patients yielded a median of 4.0 (range 2.5-6.2) Â 10 6 CD34 þ cells/kg in 2 (range 1-3) days in previous chemotherapy-mobilized patients (Figure 2a) , whereas 3.7 (range 2.0-7.9) Â 10 6 CD34 þ cells/kg were collected in 2 (range 2-3) days in previous growth factoronly mobilized patients (Figure 2b ). Patient 12, diagnosed with multiple myeloma, required two separate mobilization attempts with plerixafor and G-CSF (denoted by 12a and 12b). The patient's first collection yielded 0.5 Â 10 6 CD34 þ cells/kg. A second plerixafor and G-CSF mobilization 3 weeks later yielded an additional 1.5 Â 10 6 CD34 þ cells/kg. Combining PBSCs from all mobilizations allowed him to proceed to auto-SCT. Patient 1, diagnosed with multiple myeloma, who had failed two previous auto-SCT and two PBSC mobilization attempts, failed to mobilize using plerixafor and G-CSF. Patient 10, diagnosed with Hodgkin's disease, was unable to mobilize sufficient PBSCs during 3 days of apheresis with plerixafor and G-CSF to proceed to auto-SCT.
The kinetics of mobilization was evaluated. The highest number of circulating CD34 þ cells were seen on the first day of apheresis; in 15 of the 18 patients who achieved an adequate collection, 50% or greater of their total CD34 þ cells were collected during the first day of apheresis. These patients collected a median of 2.7 (range 1.2-7.9) Â 10 6
CD34
þ cells/kg during the first day of apheresis; a sixteenth patient, patient 12, was excluded from this analysis because of the multiple mobilization attempts. In all patients, a consistent decrease in CD34 þ cells/kg mobilization was seen after day 1 (Figures 2a and b) .
The absolute CD34 þ progenitor cells circulating in the peripheral blood increased substantially after plerixafor exposure in comparison with G-CSF treatment only (Table 2) . Following dosing with plerixafor, absolute CD34 þ count increased a median of 4.1-fold among 18 patients with exposure to plerixafor. (Patients 1 and 6 were not evaluable due to failure to collect absolute peripheral CD34 þ counts before injection with plerixafor.) These patients had a median pre-plerixafor peripheral blood CD34 þ count of 3 (range 0-26) cells/ml, whereas postplerixafor counts increased to a median of 21 (range 0-89) cells/ml. Patient 7 experienced a dramatic increase after plerixafor exposure, increasing from 0 to 18.2 cells/ml. Patients 1 and 10, who did not proceed to auto-SCT, did not have peripheral blood CD34 þ counts 45 cells/ml at any point during mobilization. Patient 12, who had two separate mobilizations with plerixafor, had peripheral blood CD34 þ counts o1 cells/ml during both series of apheresis. Throughout all mobilizations, hematological values including red blood cell count, hematocrit, hemoglobin, and platelets remained within acceptable ranges (data not shown). The most common adverse events reported involved the gastrointestinal tract and injection site reactions being primarily grade I by National Institute of Health common toxicity criteria (NIH CTC) grading. Patient 6 developed grade II nausea that required hospitalization. Rescue from failed stem cell mobilization
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Following mobilization, 16 patients proceeded to auto-SCT and were evaluable for engraftment (Table 3) . Two patients who collected sufficient CD34 þ cells did not proceed to transplant. Patient 13 elected to watch and wait and patient 19 elected alternative therapy. Nine of the sixteen received conditioning regimen consisting of BEAM, five patients were administered with high-dose melphalan and two patients received a regimen consisting of busulfan, melphalan, thiotepa (BuMelTT). The median time to neutrophil engraftment occurred on day 14 (range 10-21) and platelet engraftment (platelets 420 000 for 7 days without transfusion) was day 25 (range 13-38) (data not shown).
Discussion
These data support the observation that plerixafor (AMD3100; Mozobil), administered in conjunction with a standard mobilization cytokine (G-CSF), can be an effective means to salvage patients who had previously failed standard cytokine-assisted PBSC mobilization attempts. [26] [27] [28] Plerixafor may allow patients otherwise eligible for auto-SCT, who have failed previous mobilization attempts, an opportunity to still pursue a potentially curative procedure and to avoid the increased regimenrelated risks associated with allogeneic hematopoietic SCT.
There was a significant difference in CD34 þ progenitor cells/kg collected between the previous mobilization and the combination of plerixafor and G-CSF (P ¼ 0.001). The 20 patients collected a median of 3.8 (range 0.4-7.9) Â 10 6
CD34
þ cells/kg in 2 (range 1-3) days with the combination, and as a result 16 of 20 patients proceeded to auto-SCT. Neutrophil and platelet engraftment for the 16 transplanted patients were not different from our institutional experience with auto-SCT. Our institutional experience with auto-SCT suggests that neutrophil engraftment occurs around day 12 and platelet engraftment (platelets 420 000 for 7 days) occurs on day 24.
The safety and efficacy of plerixafor given as a s.c. injection has been evaluated in clinical trials involving healthy volunteers, HIV-infected individuals and patients with hematological malignancies. 21 Plerixafor has been shown to be generally safe and well tolerated when administered in doses from 10 to 320 mg/kg. 13, 14, 23, 24, 26 A dose-related increase in hematopoietic progenitor cells, colony forming unit-granulocyte macrophage, colony forming unit-granulocyte erythroid macrophage megakaryocyte and burst-forming unit-erythroid was seen in healthy volunteers at doses of 80, 160, 240 mg/kg. The synergistic effect of plerixafor and G-CSF has been examined in preclinical models, 17 healthy volunteers 18, 23 and in patients with multiple myeloma or non-Hodgkin's lymphoma. 19, 21, [24] [25] [26] These studies showed that there is a Table 1 . The total CD34 þ collection numbers for the failed attempt are shown on the x axis. The total CD34 þ collection numbers for the plerixafor compassionate protocol are shown on the y axis. We recognize that previous therapy can vary in number and intensity of regimens, some of which may predict for stem cell mobilization failure. Patient 1 had lenalidomide, alkylating agent exposure and two previous autologous transplants with radiation exposure, possibly contributing damage both to the hematopoietic stem cell pool and the stroma and the supportive microenvironment. Patient 12 had received spinal radiation and multiple marrow toxic agents. It is less clear why patient 10 did not mobilize after receiving standard Hodgkin's primary and salvage therapy. However, what is clear is that 17 of 20 patients successfully mobilized stem cells with plerixafor in our institutional analysis, with patient 12 also collecting enough PBSCs after a second plerixafor mobilization attempt, therefore providing transplant options to those who would otherwise be deprived of the opportunity or need to explore the option of allo-SCT.
The ability of plerixafor plus G-CSF to mobilize hematopoietic stem cells in patients who are unable to collect sufficient CD34 þ cells with G-CSF alone has been reported. 19, 27, 28 Patients undergoing their first attempt at PBSC mobilization were enrolled in a crossover design trial comparing G-CSF with G-CSF and plerixafor. 19 Nine of the patients in that study who received G-CSF as primary therapy failed to mobilize sufficient PBSCs when treated with plerixafor plus G-CSF. In contrast, all patients who received plerixafor and G-CSF as primary therapy collected adequate PBSCs. In two trials of patients receiving chemotherapy-based PBSC mobilization, plerixafor was administered on the second day of apheresis. 24, 25 These patients consistently collected more PBSCs following administration of plerixafor when compared with controls. Additionally, another independent institutional experience using plerixafor in the salvage setting has been reported in abstract form 27 confirming our observations. 29 Most recently, a larger patient experience was reported of those who have failed stem cell mobilization and received plerixafor on a compassionate use. 28 A cohort of 115 patients were assessed, and it was noted that 60% of patients with non-Hodgkin's lymphoma, 71% of patients with myeloma and 77% of patients with Hodgkin's disease who had previously failed mobilization were successful at achieving over 2 million CD34 þ progenitors/kg of body weight and could proceed on to SCT. In those patients where long-term follow-up was available, engraftment was durable and no drug-related serious adverse events were seen. (Mobilization data of four patients in this series were included in that report.) Finally, two independent phase III-randomized, doubleblind, placebo-controlled trials were performed comparing plerixafor plus G-CSF with G-CSF alone for patients with multiple myeloma or non-Hodgkin's lymphoma who were planned for auto-SCT. These data were reported recently at the American Society of Hematology meetings and were strikingly positive for patients who received pretransplant plerixafor. 30, 31 We also recognize that there are alternative strategies for stem cell mobilization to the approaches that we have undertaken. These patients represent failure of primary mobilization after growth factor alone (15) and in a minority of cases, growth factor plus chemotherapy (5).
Thus, for the majority of these patients, one could argue that successful mobilization might have occurred if higher doses of growth factor had been used originally, similar to other centers that may use 16 or 20 mg/kg/day, as a doseresponse for stem cell mobilization with G-CSF clearly exists. [32] [33] [34] However, our institution had adopted the Food and Drug Administration-approved dose schedule for 'PBPC collection and therapy for cancer patients,' which, by label, is 10 mg/kg/day by s.c or continuous infusion. 35 Using this strategy, there certainly is a possible risk of under-dosing, therefore, based on a desire to limit drug wastage. However, in review of the patient records at our institution, the dose banding to avoid drug wastage was to a slightly higher level, rather than lower level, than 10 mg/ kg/day in nearly all patients.
Thus, we confirm the ability to rescue G-CSF failures (13 of 15 patients) as well as show that those patients who fail G-CSF plus chemotherapy mobilization attempts (5 of 5 patients) can effectively be rescued with a combination of plerixafor and G-CSF. It appears that plerixafor is a promising molecule that has the potential to become a standard agent for PBSC mobilization. The results of the phase III trials will help to elucidate the role of plerixafor for primary PBSC mobilization. The ultimate role for this agent has yet to be determined. Further research is necessary to determine if this agent is best used in individuals as an adjunct when low peripheral blood CD34 cell numbers are present during mobilization, or alternatively for administration to all patients undergoing autologous transplantation. The expectation with the second scenario would be (a) that nonmobilizers will be able to be mobilized upfront and (b) that for those patients destined to collect PBSCs, that the total number of aphereses required to reach institutional target values can be decreased, thus, saving costs to the health system and improving efficiencies within the apheresis units.
